Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease
Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease
复制标题
DOI：
10.34067/kid.0007342020
复制
发表时间：
2021-07-29
期刊：
影响因子：
--
通讯作者：
Nitta, Kosaku
中科院分区：
文献类型：
--
作者：
Akihisa, Taro;Manabe, Shun;Nitta, Kosaku
这是首次报道托伐普坦治疗常染色体显性多囊肾病的剂量依赖性。体重调整后的托伐普坦平均日剂量是显著影响eGFR变化的一个因素。如果患者表现出耐受性，应考虑将托伐普坦剂量增加到最大。
Key PointsThis is the first report to describe dose dependency in the effects of tolvaptan treatment for autosomal dominant polycystic kidney disease. The weight-adjusted average daily dose of tolvaptan was found to be a factor that significantly affected the change in eGFR. If a patient shows tolerance, increasing the tolvaptan dose to the maximum should be considered.